Mavis Fujii
Neurology · Houston, TXNPI 1013099399
Payments from drug & device makers
Across 383 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$762
- Novartis$714
- AstraZeneca$712
- AbbVie$432
- Teva Pharmaceuticals USA, Inc.$405
- Sanofi$391
- plus $4K from 48 others
What the payments were for
- Speaking & faculty fees$521%
- Food & beverage$7,54999%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,613 in reported general payments places this provider in the 60th percentile of 1,246 neurology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 52 | $1,510,602 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 78 | $744,121 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 12 | $436,813 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 31 | $383,249 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 13 | $292,901 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 26 | $278,201 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $233,476 |
| BivigamImmun Glob G(Igg)/Gly/Iga Ov50 | 18 | $205,205 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 40 | $172,051 |
| UbrelvyUbrogepant | 13 | $16,533 |
| Valproate SodiumValproic Acid (As Sodium Salt) | 62 | $1,136 |
| Sodium Chloride0.9 % Sodium Chloride | 135 | $1,097 |
| Divalproex Sodium ErDivalproex Sodium | 28 | $893 |
| Pyridostigmine Bromide | 13 | $865 |
| Gabapentin | 40 | $666 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPanzyga, Octagam | $225 | $1,788,80378 claims |
| Grifols USA, LLCGamunex-C | $303 | $744,12178 claims |
| CSL BehringPrivigen, Hizentra | $132 | $555,30071 claims |
| Kedrion Biopharma, Inc.Gammaked | $43 | $292,90113 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $332 | $233,47612 claims |
| AbbVieUbrelvy | $432 | $16,53313 claims |
| Upsher-smith Laboratories LLCTopiramate | $51 | $9911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,246 neurology providers in Texas.
Other neurology in Houston
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
- John LindseyHouston$3.9M
- Joseph KassHouston$3.7M
- William OndoHouston$3.1M
- Vinay PuduvalliHouston$2.5M
- Erin Furr-StimmingHouston$2.1M
- Arjun TarakadHouston$2M
- Mazen DimachkieHouston$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.